Market Intelligence, Clinical Progress, and High-Purity Reagents for Oncolytic Virology and Solid Tumor Targeting.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for CXADR drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | CXADR ECD-Fc Fusion Protein High purity (>95%), Endotoxin controlled (<1 EU/ug). Sequence Verified. HEK293 expressed for native glycosylation. |
View CXADR Products |
| Gene Delivery | CXADR Promise-ORF / Lentivirus Full-length ORF for stable cell line construction and cell-based viral entry assays. |
View CXADR Products |
| Benchmark Ab | Anti-CXADR Recombinant Antibody Recombinant positive control derived from benchmark research clones (e.g., RmcB equivalent). |
View CXADR Products |
| Validator | CXADR siRNA Set Target-specific siRNA pool for knockdown verification in functional assays. |
View CXADR Products |
| Related Target A | CD46 Alternative adenovirus receptor; critical for assessing viral tropism and off-target entry pathways. |
View CD46 Products |
| Related Target B | DSG2 Desmoglein-2; key junctional receptor utilized by species B adenoviruses, essential for comparative tropism profiling. |
View DSG2 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Cross-species ortholog evaluation | Human, mouse, and cynomolgus CXADR recombinant proteins available with high purity (>95%) and sequence verification. |
| Conformation-dependent screening | Lentiviral transduction particles for stable cell line generation, preserving native multi-pass tight junction conformations. |
| Lack of Controls | Sequence-verified clinical-grade benchmark recombinant antibodies included |
| False Positives in Knockdown | Multiplexed siRNA validation sets included for high-specificity gene knockdown verification |
Live CXADR R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for CXADR therapeutics is intensifying, with major players shifting focus from traditional mAbs to oncolytic viral therapies and targeted antibody-drug conjugates (ADCs). As first-generation adenoviral gene therapies reach the clinic, the next wave of R&D is targeting CXADR-mediated tight junction modulation to enhance intratumoral drug delivery and therapeutic virus penetration.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Oncolytic Virus | DNAtrix, CG Oncology | Glioblastoma, Bladder Cancer | Viral entry inhibition assays (Need Lentivirus for Stable Cell Lines) |
| Antibody-Drug Conjugate (ADC) | Academic/Biotech Consortiums | Solid Tumors (Ovarian, Lung) | Internalization validation (Need high-purity ECD-Fc Fusion Protein) |
| Gene Therapy Vector | Adverum, Ferring | Bladder Cancer, Retinal Diseases | Transduction efficiency profiling (Need CXADR stable cell lines) |